Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The company's technologies deliver disease-fighting genes to address unmet needs in these patient populations. Its oncology program employs the systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to encapsulate gene-expressing plasmids targeting cancer cells. The lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is under evaluation in clinical trials for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with programs receiving FDA Fast Track and Orphan Drug designations. For diabetes, Genprex advances GPX-002, utilizing an AAV vector to deliver Pdx1 and MafA genes to the pancreas; in Type 1 diabetes, it transforms alpha cells into insulin-producing beta-like cells that evade immune detection, while in Type 2, it rejuvenates exhausted beta cells. Recent efforts include licensing additional technologies for glioblastoma treatment and advancing diabetes research with non-viral delivery systems. Founded in 2009 and headquartered in Austin, Texas, Genprex collaborates with leading institutions to expand its gene therapy pipeline in oncology and endocrinology.